AMH, Glucose Intolerance and Metabolic Syndrome in PCOS

Chulalongkorn University

Status: Unknown

Conditions: Polycystic Ovary Syndrome

Treatments: Other: serum

Study type: Observational

Funder types: Other

Identifiers

NCT02676518

057/2015

Details and patient eligibility

About

Association between serum anti-Mullerian hormone (AMH) level and prevalence of glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS)

Full description

• To study the association between serum anti-Mullerian hormone (AMH) level and glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS).

• Glucose intolerance is detected by 2-hours 75 gram oral glucose tolerance test (OGTT).

• Metabolic syndrome is diagnosed by using the Harmonized criteria; the presence of any 3 of 5 following risk factors constitutes a diagnosis of metabolic syndrome.

  1. Elevated waist circumference (> 80 cm in Asian women)
  2. Elevated triglycerides (> 150 mg/dL)
  3. Reduced HDL-cholesterol (< 50 mg/dL)
  4. Elevated blood pressure )systolic > 130 and/or diastolic > 85 mmHg)
  5. Elevated fasting glucose ( > 100 mg/dL)

• Percentage of glucose intolerance and metabolic syndrome in PCOS women as well was any differences in parameters between PCOS patients with and without glucose intolerance and metabolic syndrome will be analysed.

Enrollment: 70 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• PCOS diagnosed by Rotterdam criteria 2003

Exclusion criteria

• Pregnancy
• Previous any hormonal uses in the last 3 months
• Previous hypoglycemic drugs or insulin-sensitising agents use in the last 3 months
• Previous chemotherapy, ovarian surgery, pelvic irradiation
• Menopause

Trial design

70 participants in 1 patient group

polycystic ovary syndrome women

Description:

PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study

Treatment:

Other: serum